Search
for
Sort by
Research 91–120 of 1000+
- Cutaneous adverse effects of chemotherapy in cancer patients: A clinico epidemiological study
- Cutaneous Adverse Drug Reactions (CADRs) to COVID19 vaccines: A case series
- Cutaneous Reactions to Drugs
- Dermatologic adverse events associated with afatinib: an oral ErbB family blocker
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody–drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
- Prospective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
- Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
- Cutaneous adverse drug reaction associated with topical use of benzyl benzoate in a dog
- Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
- Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy
- Laser-Assisted Drug Delivery: A Systematic Review of Safety and Adverse Events
- A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
- Cytokine-Targeting Biologic Therapies for Alopecia Areata: A Comprehensive Review of Mechanism of Action, Clinical Efficacy, and Adverse Events
- 61349 The Development of Vitiligo After Cessation of Finasteride: Is this Part of Post-Finasteride Syndrome or an Adverse Event of Finasteride?
- Pharmacotherapy of plexiform neurofibromas in patients with neurofibromatosis type 1. Possible adverse events and their management
- Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
- Chemotherapy and the Skin: Understanding Dermatologic Side Effects
- Sun protection policies and behaviors among U.S. child care centers
- Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
- Semaglutide and the Skin: An Overview of Current Evidence
- Highlights
- Adverse Effects Associated with Long-Term Administration of Azole Antifungal Agents
- Proposal for Clinical Classification of Cutaneous Manifestations in Covid-19 and in Post Vaccination Against Sars-Cov-2: An Observational Study